Sign In
Buy NBRV
$1.42
+0 (+0%)
At Close: Nov 24, 2023
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights
08:01pm, Thursday, 12'th Mar 2020
-Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- -Reducing balance sheet risk through early paydown of a substantial portion of Hercules.
Nabriva Therapeutics Plc to Host Earnings Call
06:30pm, Thursday, 12'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Nabriva Therapeutics Plc (NASDAQ:NBRV) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at
Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020
08:01pm, Tuesday, 10'th Mar 2020
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it w
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
01:21pm, Thursday, 05'th Mar 2020
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
01:21pm, Thursday, 05'th Mar 2020
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Critical Review: Perrigo (NYSE:PRGO) & Nabriva Therapeutics (NYSE:NBRV)
06:12am, Wednesday, 04'th Mar 2020
Perrigo (NYSE:PRGO) and Nabriva Therapeutics (NASDAQ:NBRV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, ri
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09:01pm, Monday, 02'nd Mar 2020
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it h
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:01pm, Wednesday, 05'th Feb 2020
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it h
Will Nabriva Therapeutics Continue to Surge Higher?
01:24pm, Wednesday, 22'nd Jan 2020
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
